-The Indian Express Will not halt research but not rushing through decision, says Javadekar. HELPING THE government buy peace with activists protesting against granting clearance to the first transgenic food crop in the country, the biotechnology regulator on Friday deferred a decision on allowing the cultivation of a genetically-modified (GM) hybrid mustard. The Genetic Engineering Appraisal Committee (GEAC), a body under the Environment Ministry that regulates the use of genetically modified organisms (GMOs),...

-Business Standard Keeps records of deliberations and biosafety data under lock Keeping its agenda, records of discussions and results of safety trials under wraps, the environment ministry’s Genetic Engineering Appraisal Committee (GEAC) is set to decide next week whether it is safe to commercially grow genetically modified mustard. The committee is scheduled to meet on February 5 and could make a final recommendation on what could be India’s first commercially-grown genetically modified...

-The Times of India NEW DELHI: The total period of trial in corruption cases will not exceed four years with a special judge initially required to wind up proceedings in two years itself. Thereafter the trial can be extended, subject to six-month extension, states the Prevention of Corruption (Amendment) Bill, 2015 currently before the Rajya Sabha. The bill also stipulates recording of reasons for any delay in trial beyond two years and includes...

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction...

-The Times of India NEW DELHI: In an attempt to ease norms for testing and introduction of new medicines in the country, the government has taken steps to fast-track approvals for clinical trials as well as launch of drugs already approved in other countries. Pharmaceutical companies planning to launch new drugs already approved outside India after conducting pre-clinical or toxicological studies on animals will not be required to repeat such studies in...